Northwest Biotherapeutics takes $5.51M loan to keep operations funded
What's the deal? Northwest BiotherapeuticsDealroom has a profile for this one. Try Dealroom → has secured a $5,505,000 commercial loan from Streeterville CapitalDealroom has a profile for this one. Try Dealroom →, the cancer immunotherapy developer disclosed in a Form 8-K filing. The agreement, signed October 26, 2026, carries an 8% annual interest rate and a 10% original issue discount.
The terms: The loan matures in 22 months, with no repayments due for the first eight. From June 26, 2027, it will be repaid in 14 equal monthly installments at 110% of the pro rata principal, plus accrued interest. The company may pre-pay at any time, subject to a 10% fee.
Why now? Northwest Biotherapeutics is leaning on a string of financings to stay afloat. It disclosed a separate $7 million commercial loan in May 2026 and a $4.9 million convertible note from YorkvilleDealroom has a profile for this one. Try Dealroom → in July.
What's the endgame? The money is designated for ongoing business operations, the filing states. The company is pushing to prepare DCVax-L manufacturing and expand beyond glioblastoma, while its UK marketing application remains under regulatory review.
What could go wrong? A June 2026 filing reported just $0.6 million in cash and flagged substantial doubt about its ability to continue without further financing. The new loan adds to that burden: between the discount, interest, and repayment premium, it is costlier than a headline rate suggests. The agreement also includes standard default provisions, including possible acceleration.
The signal: This is liquidity, not a milestone. For a company burning cash on an unapproved pipeline, each loan buys time rather than progress — and raises the stakes on turning that runway into a marketable product.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
